Moderna stock more than doubled Wednesday after its experimental mRNA-based cancer vaccine with Merck succeeded in a late-stage trial at preventing melanoma from returning or spreading.
-- The 177% move in the stock was the Moderna's largest increase on record and the biggest gain for any stock in the S&P 500 Index in the last 25 years, according to Dow Jones Market Data.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.